Zdrowie i gospodarka · 30/08/2012

FDA Withdraws Guidance on Compendial Specifications and NDA Supplements

The Food and Drug Administration (FDA) is withdrawing Compliance Policy Guide Sec. 420.300, which pertains to changes in compendial specifications and new drug application supplements, from its Compliance Policy Guides Manual, available on the FDA's website at http://www.fda.gov/ICECI/ComplianceManuals/CompliancePolicyGuidanceManual/default.htm.